MA52896A - Composés inhibiteurs de vmat2, compositions et méthodes associées - Google Patents

Composés inhibiteurs de vmat2, compositions et méthodes associées

Info

Publication number
MA52896A
MA52896A MA052896A MA52896A MA52896A MA 52896 A MA52896 A MA 52896A MA 052896 A MA052896 A MA 052896A MA 52896 A MA52896 A MA 52896A MA 52896 A MA52896 A MA 52896A
Authority
MA
Morocco
Prior art keywords
methods
inhibitor compounds
vmat2 inhibitor
associated compositions
compositions
Prior art date
Application number
MA052896A
Other languages
English (en)
Inventor
Nicole Harriott
Christopher F O'brien
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MA52896A publication Critical patent/MA52896A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA052896A 2018-06-14 2019-06-13 Composés inhibiteurs de vmat2, compositions et méthodes associées MA52896A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862684935P 2018-06-14 2018-06-14

Publications (1)

Publication Number Publication Date
MA52896A true MA52896A (fr) 2021-04-21

Family

ID=67263041

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052896A MA52896A (fr) 2018-06-14 2019-06-13 Composés inhibiteurs de vmat2, compositions et méthodes associées

Country Status (16)

Country Link
EP (1) EP3806856A1 (fr)
JP (2) JP2021528386A (fr)
KR (1) KR20210021006A (fr)
CN (1) CN112638387A (fr)
AU (1) AU2019287524A1 (fr)
BR (1) BR112020024018A2 (fr)
CA (1) CA3100694A1 (fr)
EA (1) EA202092750A1 (fr)
IL (1) IL278758A (fr)
JO (1) JOP20200298A1 (fr)
MA (1) MA52896A (fr)
MX (1) MX2020013004A (fr)
PH (1) PH12020552088A1 (fr)
SG (1) SG11202011544UA (fr)
TW (1) TW202011963A (fr)
WO (1) WO2019241555A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016343633B2 (en) 2015-10-30 2021-07-01 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
WO2017112857A1 (fr) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
MX2020003462A (es) 2017-01-27 2020-08-03 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
MX2020002841A (es) 2017-09-21 2020-07-22 Neurocrine Biosciences Inc Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP3836926A4 (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. Procédés d'administration de certains inhibiteurs de vmat2
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN118284409A (zh) * 2021-10-29 2024-07-02 纽罗克里生物科学有限公司 缬苯那嗪组合物

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
BR9711585A (pt) 1996-10-01 2000-01-18 Cima Labs Inc Composição de microcápsula, com sabor mascarado, de um remédio solúvel em água, formulação farmacêutica para administrar um remédio, e, processo para disfarçar o sabor de um remédio.
CA2217134A1 (fr) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Formulation a liberation-retard
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DK0946169T3 (da) 1996-12-20 2003-04-22 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
BRPI0718247B1 (pt) * 2006-11-08 2021-09-21 Neurocrine Biosciences, Inc. Composto usado como inibidor do transportador de monoamina vesicular 2, composição farmacêutica compreendendo o dito composto e uso da dita composição farmacêutica no tratamento de transtornos hipercinéticos
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
BRPI0913457B8 (pt) 2008-09-18 2021-08-31 Auspex Pharmaceutical Inc Composto e composição farmacêutica
JP2013501810A (ja) 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
US8782398B2 (en) 2012-06-26 2014-07-15 Intel Corporation Secure user presence detection and authentication
US9346800B2 (en) 2012-09-18 2016-05-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
RU2021128797A (ru) 2014-02-07 2021-11-26 Ньюрокрайн Байосайенсиз, Инк. Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
PL3936130T3 (pl) 2014-05-06 2024-06-10 Neurocrine Biosciences, Inc. Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
AU2016215033B2 (en) * 2015-02-06 2020-06-25 Neurocrine Biosciences, Inc. (9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
KR20180015260A (ko) 2015-06-23 2018-02-12 뉴로크린 바이오사이언시즈 인코퍼레이티드 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
WO2018102673A1 (fr) * 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Utilisation de valbénazine pour le traitement de la schizophrénie ou d'un trouble schizo-affectif
RU2771164C2 (ru) 2017-04-01 2022-04-27 Адептио Фармасьютикалз Лимитед (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства
CA3057548A1 (fr) 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited Compositions pharmaceutiques
JOP20190239A1 (ar) * 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
MX2020002841A (es) 2017-09-21 2020-07-22 Neurocrine Biosciences Inc Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.

Also Published As

Publication number Publication date
IL278758A (en) 2021-01-31
CA3100694A1 (fr) 2019-12-19
JOP20200298A1 (ar) 2020-11-22
SG11202011544UA (en) 2020-12-30
EA202092750A1 (ru) 2021-05-13
CN112638387A (zh) 2021-04-09
MX2020013004A (es) 2021-02-17
PH12020552088A1 (en) 2021-08-02
AU2019287524A1 (en) 2020-12-24
KR20210021006A (ko) 2021-02-24
EP3806856A1 (fr) 2021-04-21
TW202011963A (zh) 2020-04-01
JP2021528386A (ja) 2021-10-21
JP2024114905A (ja) 2024-08-23
WO2019241555A1 (fr) 2019-12-19
BR112020024018A2 (pt) 2021-02-23

Similar Documents

Publication Publication Date Title
MA52896A (fr) Composés inhibiteurs de vmat2, compositions et méthodes associées
MA52560A (fr) Composés hétéroaryles tétracycliques
MA52489A (fr) Nouveaux composés
MA49858A (fr) Composés, compositions et procédés
DK4065575T3 (da) Substituerede tricycliske forbindelser
MA51669A (fr) Composés
MA45188A (fr) Oligonucléotides, compositions et méthodes associées
MA54953A (fr) Composés, compositions et procédés
MA55064A (fr) Composés utilisés comme inhibiteurs de kinase
MA49357A (fr) Composés, compositions et méthodes permettant de moduler le cftr
MA50145A (fr) Composés inhibiteurs de vmat2 et compositions de ceux-ci
MA52942A (fr) Composés inhibiteurs d'oga
MA52939A (fr) Composés inhibiteurs d'oga
MA54959A (fr) Composés, compositions et procédés
MA46242A (fr) Composés inhibiteurs de bêta-lactamase
MA47420A (fr) Composés inhibiteurs d'oga
DK3705835T3 (da) Kobling
MA45857A (fr) Composés et compositions, et utilisations associées
MA54143A (fr) Compositions et méthodes
DK3924443T3 (da) Compositions
MA50504A (fr) Composés antibactériens
MA55564A (fr) Composés de pyrrole
MA49522A (fr) Nouveaux composés de quinoléinone
MA52891A (fr) Dérivés aza-indoliques utilisés comme inhibiteurs de rho-kinase
MA56115A (fr) Composés de pyrrolidine